Optimizing Therapy for Patients with Advanced Renal Cell Carcinoma : Episode 10

News

Video

December 12, 2023

Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma

Author(s):

Expert insight into how to discuss and manage treatment-related toxicities with cancer patients and their families, emphasizing the importance of early communication and vigilance.

EP: 1.Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

EP: 2.Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

EP: 3.Imaging and Staging Considerations in Renal Cell Carcinoma

EP: 4.Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen

EP: 5.Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma

EP: 6.Comparing Treatment Combinations in Renal Cell Carcinoma

EP: 7.Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC

EP: 8.Sequencing and Second-Line Therapy in RCC: Patient Scenario

EP: 9.Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

Now Viewing

EP: 10.Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma

EP: 11.Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing

EP: 12.Triple Combination Therapies in RCC: Clinical Trial Insights

EP: 13.Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment

Related Content

November 21st 2024

Kidney Cancer NCCN Guidelines Receive Major Updates, Prostate Cancer Adds Targeted Agents

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

RP1 Plus Nivolumab in Advanced Melanoma | Image Credit: © ReisMedia - stock.adobe.com

November 11th 2024

RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy

November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

PD-L1, KIM-1 Expression in ccRCC | Image Credit: © Cornflakesei - stock.adobe.com

November 8th 2024

PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com

November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors